Serrated polyposis syndrome (SPS) is poorly defined and patients have an increased but unspecified risk for colorectal carcinoma through the serrated pathway. Despite this association SPS remains relatively obscure and is therefore likely underrecognized. We determined the frequency of SPS among patients with any serrated polyps (SPs) over a 6-month "index" period, and in doing so we assessed the ability of surgical pathologists to improve SPS detection. Particular attention was given to the index procedure to assess the potential predictive value of the findings resulting from a single colonoscopy. A total of 929 patients with at least 1 SP were identified, 17 of whom (1.8%) were determined to meet World Health Organization criteria for SPS. Nine patients met the first criterion (Z5 proximal SPs, 2 of which are >10 mm); 4 met the third criterion (> 20 SPs of any size distributed throughout the colon); and 4 met both criteria. Although no specific SP size or number at the index procedure was clearly superior in its ability to predict SPS, >50% of cases would be detected if a cutoff of Z3 SPs or a single SPZ15 mm at the index procedure is used. In summary, SPS is rare but more likely underdiagnosed. Additional studies to address the underlying genetic basis for SPS are ongoing in order to shed further light on this syndrome. Surgical pathologists are in a unique position to assist in this endeavor by identifying those patients who either meet or seem to be at high risk of meeting World Health Organization criteria.
S errated polyposis syndrome (SPS), a condition formerly known as hyperplastic polyposis, is characterized by an increased number of colorectal polyps with serrated architecture. Although SPS remains poorly understood and underrecognized, it carries a significant personal and familial risk of colorectal cancer (CRC). With a variety of clinical presentations, it may represent a group of diseases influenced by both genetic and environmental modifiers. Diagnostic criteria for SPS have been most recently defined as: (1) at least 5 serrated polyps (SPs) proximal to the sigmoid colon, 2 of which are >10 mm; or (2) any number of SPs proximal to the sigmoid colon in an individual who has a first-degree relative with SPS; or (3) >20 SPs of any size distributed throughout the colon. 25 These criteria differ from those previously published for hyperplastic polyposis in that polyps other than hyperplastic polyps (HPs) that demonstrate a serrated architecture are now being included in the definition; these include sessile serrated adenomas (SSA), traditional serrated adenomas (TSA), and polyps that have historically been designated as mixed HP/tubular adenomas but are now considered to be SSA with cytologic dysplasia (SSA-D). In addition, the third criterion has been made slightly less stringent such that it now requires >20 (rather than the previously required 30) SPs of any size distributed throughout the colon. 5 In recognition of recent advances in our understanding of the serrated pathway to CRC and the corresponding inclusion of these other types of SPs, the previous term "hyperplastic polyposis" has now been discarded in favor of "serrated polyposis."
The clinical importance of SPS pertains to its association with CRC. Although it was initially thought to not confer an increased risk for cancer, it has more recently been shown to be frequently associated with the serrated pathway to CRC. 3, 20, 21 However, cancers arising in SPS, like the SP themselves, are clinically and genetically heterogenous and are therefore not considered to represent a single disease entity. Because of the ambiguity surrounding SPS, appropriate treatment and surveillance protocols remain speculative despite the generally agreed upon need for some degree of increased surveillance.
Given the limited attention to SPS relative to familial adenomatous polyposis and Lynch syndrome, which can be at least partially explained by its previous name and the traditional belief that HPs are innocuous polyps without risk for malignant transformation, it was our a priori assumption that SPS is underrecognized. We therefore examined the frequency of SPS in a population of individuals undergoing colonoscopy for any reason and in whom any SPs were detected at this single colonoscopy. In doing so, we also assessed whether any findings available during routine practice could allow surgical pathologists to help identify those patients at risk for SPS and who therefore may benefit from closer surveillance, genetic consultation, and possible family screening.
MATERIALS AND METHODS
We retrospectively identified all surgical pathology reports with a diagnosis of at least 1 SP (HP, SSA, SSA-D, TSA) within a large, university-centered health care system over a 6-month period (March to August 2009). The endoscopic procedure performed during this timeframe was deemed the "index" procedure. All cases resulting from endoscopic biopsies were included, but surgical resections during this index period were excluded. All of these patients' previous pathology reports from within our medical center were then reviewed, and polyp type, number, and location (proximal to the sigmoid colon vs. rectosigmoid) were recorded. Data derived from all previous biopsies and surgical resections were included in determining cumulative polyp data. Polyp categories included HP, SSA, SSA-D, TSA, adenoma (including tubular, tubulovillous, and villous), and other/inflammatory polyps. The category "serrated polyp" included all HP, SSA, SSA-D, TSA, and mixed HP/tubular adenoma cases (in older reports). Endoscopy reports were also reviewed to determine polyp sizes and confirm polyp numbers and locations. It is noteworthy that all polyps detected since approximately 2005 (including the 6-mo index period) had been originally interpreted by gastrointestinal pathologists at the Ohio State University Medical Center using consistent terminology. Hematoxylin and eosinstained slides were reviewed for all cases in which the surgical pathology and endoscopy reports were insufficient to determine the polyp type, number, and/or size and for those cases for which the pathology reports utilized descriptive or confusing terminology.
In some cases the exact polyp size was not stated in the endoscopy report and could not be accurately estimated from the pathology gross description or hematoxylin and eosin-stained slide. These polyps were considered to be 1 mm if described as "diminutive" in the endoscopy report and 10 mm if designated as "large" (although we acknowledge that most of these were likely >10 mm). The number of polyps was interpreted to be 3 whenever the word "several" was used in colonoscopy reports and when the exact number could not be more precisely determined from the gross description and microscopic review (although we acknowledge that in the majority of cases there were likely more than this). In this way, any cases that remained ambiguous after reviewing the endoscopy report, pathology report, and corresponding slides were interpreted in a very conservative manner so that our ability to predict SPS would be underestimated rather than overestimated.
The current World Health Organization (WHO) definition of SPS was used to determine the number of patients meeting diagnostic criteria. 25 Because complete family history was not always available and no known histories included a family member with SPS, the second criterion (any number of proximal SPs in a first-degree relative of an individual with SPS) was not used to identify any patient with SPS. Characteristic data for this group of patients with SPS were then summarized and compared with corresponding data for the group of individuals not meeting WHO criteria. Variables that were compared included: sex; age; number, type, and size of polyps at the index procedure; and cumulative number, type, and size of polyps over the individual's lifetime (at our medical center). These variables were compared using either the nonparametric Wilcoxon rank sum tests for continuous variables or the Pearson w 2 test for categorical variables. The Holm step-down procedure was used to adjust for multiplicity, with an overall significance level of a = 0.05. To assess the predictive value of the results of a single endoscopy, sensitivity and specificity (with exact 95% binomial confidence intervals) were calculated for various cutoff values for the number and size of SPs at the index procedure.
RESULTS
A total of 929 patients with a diagnosis of at least 1 SP at the time of the index procedure were identified. This population included 459 men (49.4%) and 470 women (50.6%), with a mean age of 56.5 ± 11.3 years (range, 20 to 92 y). The vast majority of these patients (831, 89.5%) had at least 1 HP at the time of the index procedure, whereas 167 (18.0%) had at least 1 SSA. Adenomas were seen in 369 patients (39.7%), whereas smaller numbers of patients with SSA-D (19 patients, 2.0%) and inflammatory/other polyps (8 patients, 0.9%) were identified (Table 1) . No TSAs were identified during the 6-month index period, although several were identified during the review of all prior surgical pathology reports at our medical center. The mean size of the SSA and SSA-D in the entire population trended toward being larger than that of other polyp types, but this difference did not meet statistical significance.
Seventeen of the 929 patients (1.8%) with at least 1 SP qualified for a diagnosis of SPS ( Table 2 , Figs. 1, 2). This group included 7 men (41.2%) and 10 women (58.8%), with a mean age of 60.6 ± 9.3 years (range, 50 to 78 y). Neither mean age nor sex was significantly different from those patients not meeting SPS criteria. Nine patients met only the first WHO criterion (Z5 proximal SPs of which 2 are >10 mm); 4 met only the third criterion (> 20 SPs distributed throughout the colon); and 4 met both criteria. Among those patients with SPS, the mean cumulative SP count was 24.1 and the mean number of SPs at the index colonoscopy was 5.0. However, the most common number of index SPs (the mode) among these patients with SPS was 2. Eight (47.1%) of these individuals had at least 1 adenoma. Four additional patients did not fulfill the diagnostic criteria but had >15 cumulative SPs throughout the colon and will therefore likely meet the third criterion at some point in the future. Similarly, 4 additional patients did not meet the current definition but had at least 2 proximal SPs that were >10 mm (but had <5 SPs proximal to the sigmoid colon). These patients may also fulfill diagnostic criteria after future colonoscopies.
Only 3 of the 17 patients meeting SPS criteria were clinically suspected to have a polyposis syndrome, and in only 1 was SPS considered. Although none of the SPS patients had a concurrent diagnosis of cancer at the time of the index procedure, 1 patient (5.9%) did have a history of rectal cancer. Other patients had histories of nonmelanoma skin cancer (2 patients), non-Hodgkin lymphoma (1 patient), breast cancer (1 patient), and lung cancer (1 patient). Interestingly, one of the SPS patients had a diagnosis of tuberous sclerosis, a genetic disorder in which hamartomatous polyps are known to occur but which is not usually associated with serrated epithelial polyps.
The patients meeting criteria for SPS differed from those not meeting criteria in several respects ( Table 2) . They had significantly more HP, SSA, total SPs, and total SPs proximal to the sigmoid colon, both at the index procedure and cumulatively over their respective lifetimes. In addition, a higher percentage of patients with SPS had at least 1 SSA compared with patients not meeting criteria for SPS. A slightly higher proportion of SPS patients had at least 1 adenoma compared with patients without SPS, but this difference was not statistically significant.
Comparing various numbers and sizes of SPs at the index procedure yielded no clear threshold above which SPS was likely and below which it was unlikely. Ten patients with SPS (58.8%) had at least 3 SPs at the index procedure, and therefore SPS would be detected if this number is used as the cutoff above which further investigation would commence (Table 3 , Fig. 3 ). However, a total of 169 patients (18.2% of the study population) met this threshold and all of them would have to be investigated to identify these 10 patients (positive predictive value of 5.9%). Similarly, 9 patients with SPS (52.9%) had at least 1 SP at the index procedure that measured Z15 mm ( Table 4 , Fig. 4 ). A total of 62 patients (6.7% of the study population) met this threshold and would need to be investigated to detect these 9 patients (positive predictive value of 14.9%).
DISCUSSION
In this study we assessed whether surgical pathologists can help improve the currently low detection rate for serrated polyposis. The ultimate importance of improving SPS detection lies in its association with CRC. Although the majority of colon cancers are sporadic in nature, it has long been recognized that a minority of cases arise in the setting of a hereditary polyposis. In addition, an even greater number of colon cancers have a somewhat looser familial basis, with approximately 15% of all CRC cases occurring in the context of a strong genetic predisposition, including an affected first-degree relative. 1, 6, 12, 29 Much effort has gone into understanding CRC precursor lesions and CRC carcinogenesis in an attempt to minimize its prevalence, morbidity, and mortality. CRC carcinogenesis (in both sporadic and hereditary settings) has traditionally been understood in the context of the Fearon-Vogelstein model, which describes the classic adenoma-carcinoma sequence characterized by an initiating APC mutation and involvement of the Wnt signaling pathway. 10, 27 However, colon cancer is now recognized to be a heterogenous entity with multiple precursors reflecting multiple underlying molecular pathways, and it is widely accepted that a significant proportion of CRC cases have their origins in serrated lesions. 30 This purported "serrated pathway" by which these cancers evolve is estimated to account for approximately 35% of colon cancers that do not arise through the classic suppressor pathway 15, 24 and is usually characterized by early BRAF mutations and subsequent CRC with high-level CpG island methylation (CIMP-high phenotype) and microsatellite instability. The possibility of a familial syndrome with origins in this newer pathway was first proposed in the 1990s, 16, 18 and a potentially significant role of this pathway in familial CRC seems highly probable given that the 2 best understood forms of hereditary CRC (familial adenomatous polyposis, Lynch syndrome) combine to account for only 2% to 5% of all cases. 29 As currently understood, SPS may in fact represent the phenotypic end of a spectrum of a fairly widespread genetic predisposition in the population that is associated with a very significant number of colon cancers. 2, 3, 30 The hereditary mixed polyposis syndrome is a similar, but possibly distinct, condition, with the few described families having an autosomal dominant inheritance pattern. It is characterized by a variety of polyp types including conventional adenomas, SPs, and atypical juvenile polyps, and there is an associated increased risk for CRC. Individuals and families with hereditary mixed polyposis syndrome may also have mixtures of these polyp types and polyps containing mixed patterns, with the polyps typically confined to the colon and rectum. 28 SPS was first described in the literature in the late 1970s but is still not well characterized. 26 A single published estimate cites a frequency of 1 in 3000, a number determined from asymptomatic patients aged 55 to 64 years undergoing screening colonoscopy. 21 Although we detected 17 patients meeting criteria for SPS during our 6-month study period, we have almost certainly underestimated the true frequency of SPS in our population given our purposefully conservative interpretation of any ambiguous data and lack of complete family histories. The notion that SPS is underrecognized is also supported by the fact that only 3 of our 17 patients were clinically suspected to have a polyposis syndrome. Although many patients with CRC and concurrent SPS have been reported, the reported rates of this association are highly variable. 4, 7, 8, 13, 14, 17, 19, 22, 23 A recent report by Buchanan and colleagues summarized the known published series of SPS cases with >5 individuals, and rates of associated CRC ranged from 0% to 77%. 4, 11, 22, 23 One of the 17 patients detected in our study had a previous diagnosis of rectal cancer (5.9%), placing our CRC association at the lower end of the reported spectrum. One possible explanation for this wide variation is the manner in which subjects were selected. In contrast to our study in which all patients undergoing colonoscopy for any reason were evaluated, many previous studies have recruited patients from cancer genetics clinics, a methodology that may falsely elevate the reported association with CRC. SPS is underrecognized for several potential reasons. Perhaps most importantly there is a general lack of awareness in the medical community regarding both its existence and its potential role in a proportion of hereditary colon cancers. In addition, the diagnosis is frequently based on cumulative lifetime findings, as patients with SPS rarely present with an overwhelming number of polyps at a single point in time. As such, many patients escape detection if their physicians are not actively seeking to make this diagnosis, a problem that is exacerbated by the fact that patients frequently receive care at multiple institutions. In an attempt to determine cutoff points that may help surgical pathologists decide when to suggest further investigation for SPS, we examined polyp characteristics at a single endoscopy to determine whether any had predictive value in determining which patients may be at higher risk for SPS. If the findings at a single procedure raise a sufficient degree of suspicion, a comment in the pathology report may be warranted to suggest the possibility of SPS and recommend further clinical assessment and/or genetic consultation.
Given that 2 of the 3 SPS criteria are defined by SP number, we first examined whether the number of SPs at a single procedure has any predictive value. More than half of our patients with SPS (10/17, 58.8%) would have been detected if a cutoff of Z3 SPs at the index procedure had been used to determine those patients needing closer inspection. At this cutoff point, however, 169 patients would have to have been flagged and further investigated to detect those 10 patients with SPS (positive predictive value of 5.9%). Examining other SP number cutoff values shows a relatively smooth continuum of sensitivity and specificity, demonstrating that no threshold number of SPs at a single procedure is clearly a superior choice for identifying at-risk patients (Fig. 1) , although it is clear that greater numbers raise the probability of SPS. In a similar manner, the size of SPs at the index colonoscopy was examined in an attempt to determine whether sizes above a certain value clearly indicated a higher likelihood of SPS. The smallest SP size that still detected more than half (9/17, 52.9%) of the patients meeting SPS criteria was 15 mm. At this cutoff point, 62 patients would need to have been flagged as high risk and subjected to further investigation to detect 9 patients meeting diagnostic criteria (positive predictive value of 14.5%). Similar to SP number, moving the threshold SP size up or down yielded no obvious threshold above which SPS became very likely (Fig. 2) . Although no definitive conclusions can be drawn from these data, it appears that fewer numbers of patients would be flagged for further investigation if polyp size rather than number is used as the variable of choice (62 patients vs. 169 patients in our population, if a sensitivity of >50% is desired).
The ability to compare our findings with those of other studies is limited by the use of differing definitional criteria across studies, a difficulty that is exacerbated by the fact that these criteria have undergone change. An additional but unavoidable limitation of our study is that we have attempted to compare polyp size and number with a clinical syndrome, the definition of which is derived from these same polyp characteristics. It therefore comes as no surprise that patients meeting criteria for SPS have more SPs compared with patients not meeting diagnostic criteria. However, it remains true that until more patients with this syndrome are detected and studied a more satisfactory and likely molecular definition will remain elusive. To this end, increasing detection will not only improve the health of patients and their family members but will also allow the medical community to collect material (detailed family histories and tissue samples for molecular studies) to achieve greater understanding of SPS. It is our opinion that pathologists are well poised to drive further investigation of SPS toward both of these ends.
Although the degree of increased CRC risk is still not well defined, some recent studies have provided speculative management recommendations with surveillance intervals ranging from 1 to 3 years. Some authors have advocated removing all polyps by whatever means necessary, whereas others have recommended removal of only proximally located or larger (> 5 mm) polyps. 3, 8, 9, 24 In addition, it has been suggested that consideration for at least proximal colectomy be given in the case of patients with SPS who develop SSA-D. 24 In conclusion, SPS is a relatively rare but underrecognized syndrome that is characterized by an increased risk for CRC. Although both number and size of SPs at a single point in time have relatively low predictive values for SPS, any contribution made by surgical pathologists is clinically important, given that the vast majority of SPS cases are going undetected using current methods. Improving the detection of SPS will serve multiple purposes, including further defining SPS and its associated risk for CRC, identifying patients and providing material to be used in ongoing gene discovery studies, and allowing the medical community to devise better informed surveillance/ treatment protocols for affected patients and their family members. Although it remains difficult to recommend an exact threshold for either SP number or SP size above which the possibility of SPS should be considered, it seems clear that a multidisciplinary approach with improved communication will be necessary and that surgical pathologists are in a unique position to assist in this effort.
